 | • レポートコード：MRC2305C023 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、233ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、世界のコンパニオン診断市場規模が2021年に2,116.56百万ドル、2022年に2,355.10百万ドルとなり、更に年平均11.44％成長して2027年には4,055.49百万ドルに達すると予測しています。当市場調査レポートでは、コンパニオン診断の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別分析（免疫組織化学、In situハイブリダイゼーション、次世代シーケンシング、ポリメラーゼ連鎖反応）、疾患別分析（乳がん、結腸直腸がん、白血病、肺がん、黒色腫）、エンドユーザー別分析（バイオ医薬品企業、医薬品企業、リファレンスラボ）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、当書には、Abbott Laboratories、Abnova Corporation、Agilent Technologies, Inc.、Almac Group、Amoy Diagnostics Co., Ltd.、Archerdx, Inc.、ARUP Laboratories、Biogenex Laboratories, Inc、bioMérieux SA、Danaher Corporation、Eli Lilly and Companyなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のコンパニオン診断市場規模：技術別 - 免疫組織化学の市場規模 - In situハイブリダイゼーションの市場規模 - 次世代シーケンシングの市場規模 - ポリメラーゼ連鎖反応の市場規模 ・世界のコンパニオン診断市場規模：疾患別 - 乳がんにおける市場規模 - 結腸直腸がんにおける市場規模 - 白血病における市場規模 - 肺がんにおける市場規模 - 黒色腫における市場規模 ・世界のコンパニオン診断市場規模：エンドユーザー別 - バイオ医薬品企業における市場規模 - 医薬品企業における市場規模 - リファレンスラボにおける市場規模 ・世界のコンパニオン診断市場規模：地域別 - 南北アメリカのコンパニオン診断市場規模 アメリカのコンパニオン診断市場規模 カナダのコンパニオン診断市場規模 ブラジルのコンパニオン診断市場規模 ... - アジア太平洋のコンパニオン診断市場規模 日本のコンパニオン診断市場規模 中国のコンパニオン診断市場規模 インドのコンパニオン診断市場規模 韓国のコンパニオン診断市場規模 台湾のコンパニオン診断市場規模 ... - ヨーロッパ/中東/アフリカのコンパニオン診断市場規模 イギリスのコンパニオン診断市場規模 ドイツのコンパニオン診断市場規模 フランスのコンパニオン診断市場規模 ロシアのコンパニオン診断市場規模 ... - その他地域のコンパニオン診断市場規模 ・競争状況 ・企業情報 |
The Global Companion Diagnostics Market size was estimated at USD 2,116.56 million in 2021 and expected to reach USD 2,355.10 million in 2022, and is projected to grow at a CAGR 11.44% to reach USD 4,055.49 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Companion Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technology, the market was studied across Immunohistochemistry, In Situ Hybridization, Next-generation Sequencing, and Polymerase Chain Reaction.
Based on Indication, the market was studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, and Melanoma.
Based on End User, the market was studied across Biopharmaceutical Companies, Pharmaceutical, and Reference Laboratories.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Companion Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Companion Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Companion Diagnostics Market, including Abbott Laboratories, Abnova Corporation, Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., Archerdx, Inc., ARUP Laboratories, Biogenex Laboratories, Inc, bioMérieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, FOUNDATION MEDICINE, INC., Guardant Health, Inc, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, Q2 Solutions, R-Biopharm AG, Siemens Healthcare Private Limited, Sysmex Corporation, and Thermo Fisher Scientific Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Companion Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Companion Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Companion Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Companion Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Companion Diagnostics Market?
6. What is the market share of the leading vendors in the Global Companion Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Companion Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic diseases
5.1.1.2. Growing demand for personalized medicines and targeted therapy
5.1.2. Restraints
5.1.2.1. High costs of companion diagnostics
5.1.3. Opportunities
5.1.3.1. Technological advancements in diagnostic techniques
5.1.3.2. Growing approval rate for companion diagnostics
5.1.4. Challenges
5.1.4.1. Reimbursement issues associated with companion diagnostic tests
5.2. Cumulative Impact of COVID-19
6. Companion Diagnostics Market, by Technology
6.1. Introduction
6.2. Immunohistochemistry
6.3. In Situ Hybridization
6.4. Next-generation Sequencing
6.5. Polymerase Chain Reaction
7. Companion Diagnostics Market, by Indication
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Leukemia
7.5. Lung Cancer
7.6. Melanoma
8. Companion Diagnostics Market, by End User
8.1. Introduction
8.2. Biopharmaceutical Companies
8.3. Pharmaceutical
8.4. Reference Laboratories
9. Americas Companion Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Companion Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Companion Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Abnova Corporation
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Agilent Technologies, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Almac Group
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Amoy Diagnostics Co., Ltd.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Archerdx, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. ARUP Laboratories
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Biogenex Laboratories, Inc
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. bioMérieux SA
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Danaher Corporation
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Eli Lilly and Company
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. F. Hoffmann-La Roche AG
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. FOUNDATION MEDICINE, INC.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Guardant Health, Inc
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Illumina, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Invivoscribe Technologies, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Myriad Genetics, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. NG biotech
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Q2 Solutions
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. R-Biopharm AG
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Siemens Healthcare Private Limited
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Sysmex Corporation
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Thermo Fisher Scientific Inc.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing